S Cinieri
Overview
Explore the profile of S Cinieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gravina A, Gargiulo P, De Laurentiis M, Arenare L, De Placido S, Orditura M, et al.
ESMO Open
. 2025 Jan;
10(1):104085.
PMID: 39754976
Background: The Hormonal Bone Effects (HOBOE) study tested whether adjuvant triptorelin plus either letrozole (L) or zoledronic acid (Z) plus L (ZL) was more effective than tamoxifen (T) in premenopausal...
2.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, et al.
Ann Oncol
. 2024 May;
35(7):667-676.
PMID: 38704093
Background: Immunotherapy combined with chemotherapy significantly improves progression-free survival (PFS) compared to first-line chemotherapy alone in advanced endometrial cancer (EC), with a much larger effect size in microsatellite instability-high (MSI-H)...
3.
Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, et al.
ESMO Open
. 2024 Mar;
9(4):102943.
PMID: 38492275
Background: In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data...
4.
Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM)
Berardi R, Rossi F, Papa R, Appetecchia M, Baggio G, Bianchini M, et al.
ESMO Open
. 2024 Feb;
9(2):102243.
PMID: 38394984
Background: Following the development of gender medicine in the past 20 years, more recently in the field of oncology an increasing amount of evidence suggests gender differences in the epidemiology...
5.
Incorvaia L, Badalamenti G, Novo G, Gori S, Cortesi L, Brando C, et al.
ESMO Open
. 2023 Dec;
9(1):102196.
PMID: 38118367
Background: The BRCA proteins play a key role in the homologous recombination (HR) pathway. Beyond BRCA1/2, other genes are involved in the HR repair (HRR). Due to the prominent role...
6.
Silvestris N, Franchina T, Gallo M, Argentiero A, Avogaro A, Cirino G, et al.
ESMO Open
. 2023 Dec;
8(6):102062.
PMID: 38070434
Cancer management has significantly evolved in recent years, focusing on a multidisciplinary team approach to provide the best possible patient care and address the various comorbidities, toxicities, and complications that...
7.
Arenare L, Porta C, Barberio D, Terzolo S, Zagonel V, Pisconti S, et al.
ESMO Open
. 2023 Dec;
8(6):102192.
PMID: 38052104
Background: The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire was developed to measure financial toxicity (FT) and identify its determinants. The aim of the present study was to...
8.
Trevisan B, Pepe F, Vallini I, Montagna E, Amoroso D, Berardi R, et al.
Sci Rep
. 2023 Jul;
13(1):12255.
PMID: 37507480
Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and...
9.
Miglietta F, Fabi A, Generali D, Dieci M, Arpino G, Bianchini G, et al.
Cancer Treat Rev
. 2023 Jul;
119:102594.
PMID: 37400291
No abstract available.
10.
Leone A, Miceli R, Trapani D, Massagrande M, Morano F, Marsoni S, et al.
ESMO Open
. 2023 Jun;
8(3):101578.
PMID: 37270870
Background: Transgender and gender-diverse (TGD) population represents an underserved group across the cancer care continuum. To assess the perspective of both oncology health care providers (OHPs) and TGD individuals in...